Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6MTA

KRAS P34R mutant structure in complex with GTP analogue

Summary for 6MTA
Entry DOI10.2210/pdb6mta/pdb
DescriptorGTPase KRas, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, ... (4 entities in total)
Functional Keywordsgtpase kras hydrolysis, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains3
Total formula weight59635.02
Authors
Bera, A.K.,Westover, K.D. (deposition date: 2018-10-19, release date: 2020-04-15, Last modification date: 2023-10-11)
Primary citationBera, A.K.,Lu, J.,Lu, C.,Li, L.,Gondi, S.,Yan, W.,Nelson, A.,Zhang, G.,Westover, K.D.
GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R.
Birth Defects Res, 112:708-717, 2020
Cited by
PubMed Abstract: RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRAS seen in NS and CFCS. GTP and GDP-bound KRAS crystallized in multiple forms, with each lattice consisting of multiple protein conformations. In all GTP-bound conformations, the switch regions are not compatible with GAP binding, suggesting a structural mechanism for the GAP insensitivity of this RAS mutant. However, GTP-bound conformations are compatible with intrinsic nucleotide hydrolysis, including one that places R34 in a position analogous to the GAP arginine finger or intrinsic arginine finger found in heterotrimeric G proteins, which may support intrinsic GTP hydrolysis. We also note that the affinity between KRAS and RAF-RBD is decreased, suggesting another possible mechanism for dampening of RAS signaling. These results may provide a foothold for development of new mutation-specific strategies to address KRAS -driven diseases.
PubMed: 32187889
DOI: 10.1002/bdr2.1647
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.15 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon